WHO says anything short of full trial disclosure skews public spending

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Medicine, Health care

WHO calls for Full trial disclosure
WHO calls for Full trial disclosure
Drug, vaccine and medical device developers should publish all trial results according to the WHO, which says anything less skews R&D priorities and public healthcare investment.

World Health Organisation (WHO) Assistant Director General for Health Systems and Innovation Marie-Paule Kieny called for greater disclosure today​, arguing that full disclosure "underpins the principal goal of medical research: to serve the betterment of humanity.​”

Failure to publicly disclose trial results engenders misinformation, leading to skewed priorities for both R&D and public health interventions​” said Kieny, adding "it creates indirect costs for public and private entities, including patients themselves, who pay for suboptimal or harmful treatments.​”

Last month a report in the New England Journal of Medicine (NEJM) revealed that the vast majority​ of results from clinical trials are not reported on ClinicalTrials.gov within a year of their ending.

An earlier study​ of vaccine trials registered in various databases revealed that full results from only 29% had been published in a peer-reviewed journal within 24 months of completion, which is the target timescale the WHO recommends.

Trial registry

In 2005 the WHO called for unambiguous identification of all interventional clinical trials and established the International Clinical Trials Registry Platform, which collates information on trials that have been notified in a network of clinical trial registries.

The WHO's comments fit with those of the US Institute of Medicine (IOM)​, UK politicians​, Ben Goldacre's Alltrials​ organisation.

Members of the European parliament passed a law​ designed to force drugmakers to publish clinical trial results this time last year.

The European Medicines Agency (EMA) already hosts a trial database​, however the agency has not yet decided how the additional information required by the new legislation​ will be made public​.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more